Newsroom

26

May 2020

Tuesday

iX Biopharma Ltd. is pleased to announce that it has commenced supply of Wafesil® and Silcap®, which are medicines for the treatment of male erectile dysfunction, through telemedicine in Australia.

More information can be found in the attached press release.

11

May 2020

Monday

Read our update on impact of COVID-19 on business operations from iX Biopharma Chairman & CEO here.

06

May 2020

Wednesday

iX Biopharma Group’s Xativa product, the world’s first medicinal cannabis sublingual wafer, has been featured on Channel 9 News Brisbane.


Watch the news feature here

Read more

04

May 2020

Monday

Entity has seen exceptional demand for its LumeniX and RestoriX nutraceutical products less than three weeks into the opening of Entity flagship stores on JD Worldwide and Tmall Global.

More information can be found in the attached press release.

29

April 2020

Wednesday

iX Biopharma inks agreement with Cannatrek to supply Xativa™, the world’s first freeze-dried sublingual medicinal cannabis wafer, to the Australian market.

More information can be found in the attached press release.

27

April 2020

Monday

iX Biopharma Ltd is pleased to announce that it has entered into a licensing agreement with Yiling Pharmaceutical Ltd. for the licensing, supply and distribution of Wafesil™, a sublingual sildenafil wafer for the treatment of male erectile dysfunction, in China.

More information can be found in the attached press release.

13

April 2020

Monday

iX Biopharma Ltd is pleased to announce the opening of Entity’s new flagship store on Tmall Global (“Tmall”), Alibaba Group’s cross-border B2C e-commerce platform.

More information can be found in the attached press release.

 

06

April 2020

Monday

iX Biopharma Ltd is pleased to announce the opening of the Entity flagship store on JD Worldwide, JD.com’s cross-border e-commerce platform. JD Worldwide provides a platform for Chinese consumers to purchase authentic imported products and enables international suppliers to sell directly to Chinese consumers without requiring an established presence in China.

More information can be found in the attached press release.

 

11

February 2020

Tuesday

iX Biopharma Ltd. has reported results for the second quarter and/or half yearly results as of 31 December 2019.

The second quarter financial statements for the period can be found here.

30

January 2020

Thursday

iX Biopharma Ltd has published its presentation for Phillip securities Jan 2020.

The presentation can be found here.

For all company announcements, please refer to SGX company disclosures page.

Contact us

iX Biopharma Ltd

1 Kim Seng Promenade
#14-01 Great World City East Tower
Singapore 237994
T: +65 6235 2270
F: +65 6235 2170
E: info@ixbiopharma.com